SOPHiA GENETICS (SOPH) Competitors

SOPHiA GENETICS (NASDAQ:SOPH) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Do insiders and institutionals believe in SOPH or TRVI?

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Do analysts recommend SOPH or TRVI?

SOPHiA GENETICS presently has a consensus price target of $8.00, indicating a potential upside of 121.61%. Trevi Therapeutics has a consensus price target of $20.11, indicating a potential upside of 166.37%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Trevi Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Which has preferable earnings & valuation, SOPH or TRVI?

Trevi Therapeutics has lower revenue, but higher earnings than SOPHiA GENETICS. Trevi Therapeutics is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$65.17M	3.74	-$62.49M	-$0.44	-8.20
Trevi Therapeutics	N/A	N/A	-$47.91M	-$0.42	-17.98

Is SOPH or TRVI more profitable?

Trevi Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -40.99%. SOPHiA GENETICS's return on equity of -30.69% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-40.99%	-30.69%	-17.39%
Trevi Therapeutics	N/A	-41.44%	-38.21%

Which has more volatility and risk, SOPH or TRVI?

SOPHiA GENETICS has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Trevi Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Does the media favor SOPH or TRVI?

In the previous week, Trevi Therapeutics had 9 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 10 mentions for Trevi Therapeutics and 1 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 1.92 beat Trevi Therapeutics' score of 0.80 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Trevi Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Trevi Therapeutics beats SOPHiA GENETICS on 10 of the 16 factors compared between the two stocks.